/
These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties and assumptions that are difficult to predict. In addition, these statements include the impact of economic and market conditions on us and our clients, the effects of our cost-saving actions, including on an annualized basis, and the steps to optimize returns to shareholders on an ef…
$224.35
$4.81 (-2.10%)
EOD Jul 17, 2026
Operating margin is thin at 0.63%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 0.9% YoY. Margins deteriorated 5.0pp alongside, both lines moving the wrong way.
ROIC dropped from 2.45% to 0.33%, capital efficiency is deteriorating. Net debt of $2.44B represents 4.7x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4.03B
▼ -0.9% YoY
Net Income (TTM)
-$185M
▼ -750.1% YoY
Op. Margin
1.75%
▼ -5.0pp YoY
ROIC
0.88%
▼ -2.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$391M
▲ +3.4% YoY
Op. Cash Flow (TTM)
$607M
▲ +0.4% YoY
Net Debt
$2.88B
Cash & Equiv.
$192M
5Y CAGR: +6.5%
5Y CAGR: +6.4%
Continue Research
Charles River Laboratories International (CRL) trades above a two-stage DCF intrinsic value of about $79.62 per share, so at $224.35 the stock looks overvalued (64.5% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Charles River Laboratories International scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $79.62 per share for CRL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $59.72. At today's $224.35, that puts the stock about 64.5% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Charles River Laboratories International scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 1.7% operating margin and a 0.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CRL currently trades above its estimated intrinsic value and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.